Literature DB >> 29573976

The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy.

Richard G Vile1.   

Abstract

Mesh：

Year:  2018        PMID： 29573976      PMCID： PMC6080132          DOI： 10.1016/j.ymthe.2018.03.007

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  28 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Authors:  Phonphimon Wongthida; Rosa Maria Diaz; Feorillo Galivo; Timothy Kottke; Jill Thompson; Jose Pulido; Kevin Pavelko; Larry Pease; Alan Melcher; Richard Vile
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

Review 3.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

4.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

5.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

Review 6.  Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded.

Authors:  Roberto Cattaneo; Tanner Miest; Elena V Shashkova; Michael A Barry
Journal:  Nat Rev Microbiol       Date:  2008-07       Impact factor: 60.633

7.  Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Authors:  Elizabeth Ilett; Timothy Kottke; Oliver Donnelly; Jill Thompson; Candice Willmon; Rosa Diaz; Shane Zaidi; Matt Coffey; Peter Selby; Kevin Harrington; Hardev Pandha; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2014-06-24       Impact factor: 11.454

Review 8.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

9.  Immature dengue virus: a veiled pathogen?

Authors:  Izabela A Rodenhuis-Zybert; Hilde M van der Schaar; Júlia M da Silva Voorham; Heidi van der Ende-Metselaar; Huan-Yao Lei; Jan Wilschut; Jolanda M Smit
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

10.  The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Authors:  Diana M Rommelfanger; Marta Compte; Marta C Grau; Rosa M Diaz; Elizabeth Ilett; Luis Alvarez-Vallina; Jill M Thompson; Timothy J Kottke; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2012-09-25       Impact factor: 11.454
View more
  5 in total

1.  Targeted Delivery of IL-12 Adjuvants Immunotherapy by Oncolytic Viruses.

Authors:  Andrea Vannini; Valerio Leoni; Gabriella Campadelli-Fiume
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency.

Authors:  Yu-Shui Ma; Xiao-Feng Wang; Yun-Jie Zhang; Pei Luo; Hui-Deng Long; Liu Li; Hui-Qiong Yang; Ru-Ting Xie; Cheng-You Jia; Gai-Xia Lu; Zheng-Yan Chang; Jia-Jia Zhang; Shao-Bo Xue; Zhong-Wei Lv; Fei Yu; Qing Xia; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200

3.  Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer.

Authors:  Ashley A Stegelmeier; Thomas M McAusland; Elaine M Klafuric; Jacob P van Vloten; Kathy Matuszewska; Mark A A Minow; Jessica A Minott; Lisa A Santry; Madison Pereira; Khalil Karimi; Joseph Colasanti; D Grant McFadden; James J Petrik; Byram W Bridle; Sarah K Wootton
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

4.  Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens.

Authors:  Paula Jaime-Sanchez; Iratxe Uranga-Murillo; Nacho Aguilo; Sofia C Khouili; Maykel A Arias; David Sancho; Julian Pardo
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

Review 5.  Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Authors:  Alexander Malogolovkin; Nizami Gasanov; Alexander Egorov; Marianna Weener; Roman Ivanov; Alexander Karabelsky
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.